Literature DB >> 11123058

Clinical trials review: idiopathic inflammatory myopathy.

C V Oddis1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123058     DOI: 10.1007/s11926-000-0078-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  7 in total

1.  Tacrolimus in refractory polymyositis with interstitial lung disease.

Authors:  C V Oddis; F C Sciurba; K A Elmagd; T E Starzl
Journal:  Lancet       Date:  1999-05-22       Impact factor: 79.321

2.  Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients.

Authors:  G F Wiesinger; M Quittan; M Graninger; A Seeber; G Ebenbichler; B Sturm; K Kerschan; J Smolen; W Graninger
Journal:  Br J Rheumatol       Date:  1998-12

3.  Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme.

Authors:  G F Wiesinger; M Quittan; M Aringer; A Seeber; B Volc-Platzer; J Smolen; W Graninger
Journal:  Br J Rheumatol       Date:  1998-02

Review 4.  Dermatomyositis.

Authors:  J P Callen
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

5.  Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens.

Authors:  L Villalba; J E Hicks; E M Adams; J B Sherman; M F Gourley; R L Leff; B C Thornton; S H Burgess; P H Plotz; F W Miller
Journal:  Arthritis Rheum       Date:  1998-03

6.  A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures.

Authors:  E M Adams; F Pucino; C Yarboro; J E Hicks; B Thornton; C McGarvey; B C Sonies; M L Bartlett; M L Villalba; T Fleisher; P H Plotz
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

7.  Resistive exercise in the rehabilitation of polymyositis/dermatomyositis.

Authors:  A Escalante; L Miller; T D Beardmore
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.